RxDoctor Payments Data

Whitney Rust

Family · Thibodaux, LANPI 1477048874

Payments from drug & device makers

$1,632in general payments, 2019–2025

Across 61 payments — averaging $26.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medline Industries LP$326
  • Neurocrine Biosciences, Inc.$162
  • AbbVie$151
  • Teva Pharmaceuticals USA, Inc.$125
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$125
  • Boehringer Ingelheim$109
  • plus $633 from 22 others

What the payments were for

  • Food & beverage$1,632100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,632 in reported general payments places this provider in the 70th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$91,270
Medicare patients
220
Services billed
1,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$49,171
RexultiBrexpiprazole38$27,087
NuedextaDextromethorphan Hbr/Quinidine25$18,963
FycompaPerampanel21$12,749
FarxigaDapagliflozin Propanediol22$7,385
EliquisApixaban20$5,641
JanuviaSitagliptin Phosphate14$5,340
EntrestoSacubitril/Valsartan12$3,953
GemtesaVibegron14$3,427
Pantoprazole Sodium59$3,053
Scopolamine23$2,219
Gabapentin102$2,201
Donepezil Hcl50$1,990
Albuterol Sulfate HfaAlbuterol Sulfate36$1,782
Sucralfate35$1,681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$35$49,17148 claims
Otsuka America Pharmaceutical, Inc.Rexulti$35$27,08738 claims
Eisai Inc.Fycompa$34$12,74921 claims
AstraZenecaFarxiga$91$7,38522 claims
MerckJanuvia$14$5,34014 claims
NovartisEntresto$25$3,95312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,610 family providers in Louisiana.

Other family in Thibodaux

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →